Astellas Terminates Agreement On Acute Heart Failure Agent Carperitide
Sun, 28 Jan 2007 08:00 AM EST
... Astellas Pharma Inc. today announced that its US affiliate, Astellas US LLC, has terminated its license agreement with Daiichi Asubio Pharma Co., Ltd. (Tokyo) regarding North American and European Union rights to carperitide for the treatment of acute heart failure.Astellas US LLC's predecessor, Fujisawa Healthcare, Inc. and Daiichi Asubio Pharma's predecessor, Daiichi Suntory Pharma Co., Ltd. [click link for full article] ...
Related Topics
- Congestive Heart Failure
- Kidney Failure
- Agent Orange
- Chemical Agents
- Heart Attack
- Heart Disease
- BNP
- Heart Murmur
- Coronary Heart Disease
- Heart Defects
- Heart Diseases
- Acute Care
- Heart and Circulation
- Congenital Heart Disease
- Heart Bypass Surgery
- Angina
- Carvedilol
- Heart Diseases--Prevention
- Coronary Disease
- Riot Control Agents

Not Signed In -


